12/18
07:52 am
sln
Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]
Medium
Report
Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]
12/10
08:00 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
High
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
12/9
05:31 pm
sln
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
Medium
Report
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
12/9
05:31 pm
sln
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
Medium
Report
The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight Insights
12/9
10:55 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
12/9
07:30 am
sln
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Medium
Report
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
12/2
10:14 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets.
11/26
08:00 am
sln
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
11/21
08:17 am
sln
New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]
High
Report
New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]
11/20
01:19 pm
sln
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]
Medium
Report
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]
11/19
11:41 am
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.
11/18
02:33 pm
sln
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]
Medium
Report
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]
11/18
02:30 pm
sln
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Medium
Report
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
11/15
03:26 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/14
05:25 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
Medium
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
11/14
03:27 pm
sln
Silence Therapeutics reports Q3 results [Seeking Alpha]
Low
Report
Silence Therapeutics reports Q3 results [Seeking Alpha]
11/14
08:00 am
sln
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13
08:00 am
sln
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Medium
Report
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
10/28
01:12 pm
sln
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely [Yahoo! Finance]
10/22
05:36 pm
sln
Silence Therapeutics files for ordinary shares offering [Seeking Alpha]
Low
Report
Silence Therapeutics files for ordinary shares offering [Seeking Alpha]
10/8
12:57 pm
sln
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $49.00 price target on the stock.
Low
Report
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $49.00 price target on the stock.